EGFR-targeted therapeutics have been explored in a large number of human malignancies and have shown clinical activity in subsets of patients with non-small cell lung cancer (NSCLC), glioblastoma, squamous cell carcinomas of the head and neck, colorectal carcinoma, and certain other malignancies [12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.